Ropidoxuridine

Shuttle Pharma expands Phase II trial of ropidoxuridine for glioblastoma, dosing first cohort at US cancer centers. The trial, combining ropidoxuridine with radiation therapy, aims to treat IDH wild-type, methylation-negative glioblastomas at multiple sites including UVA Cancer Center. Shuttle Pharma CEO Anatoly Dritschilo highlights the strategic alignment with nationally recognized cancer centers to advance the trial.

Shuttle Pharmaceuticals announced first patient enrollment and dosing in its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma at UVA Cancer Center, one of six centers conducting the trial. The trial aims to determine an optimal dose among 40 patients and will focus on IDH wild-type, methylation negative glioblastoma patients, who currently have a survival rate of less than 12 months.

Shuttle Pharmaceuticals announced first patient enrollment and dosing in its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma at UVA Cancer Center, one of six centers conducting the trial. The trial aims to determine an optimal dose among 40 patients and will focus on IDH wild-type, methylation negative glioblastoma patients, who currently have radiation as the standard of care.

Shuttle Pharmaceuticals Holdings (SHPH) announced the enrollment and dosing of its first patient at UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment. The trial, conducted across six cancer centers, will initially include 40 patients randomized into two doses (20 @ 1,200 mg/day and 20 @ 960 mg/day), followed by an additional 14 patients at the optimal dose. The study targets IDH wild-type, methylation negative glioblastoma patients, who currently have treatment options with radiation therapy. The company previously received FDA Orphan Drug Designation for Ropidoxuridine.

Shuttle Pharmaceuticals initiates Phase 2 trial of Ropidoxuridine at UVA Cancer Center for glioblastoma treatment, with 40 patients randomized into two doses to determine optimal effectiveness. The trial aims to improve survival rates in IDH wild-type, methylation negative glioblastoma patients, currently treated only with radiation.

Shuttle Pharmaceuticals Holdings, Inc. closed a public offering on Oct 29, 2024, raising $4.5M. Funds will advance IND-enabling activities and Phase I/II trials, with $2.3M allocated to Theradex Systems for Ropidoxuridine's Phase II trials. The offering included pre-funded warrants, common stock purchase warrants, and common stock shares. A securities purchase agreement and placement agency agreement were also executed.

Shuttle Pharmaceuticals has initiated a Phase II trial of Ropidoxuridine, a radiation sensitiser for treating glioblastoma, dosing its first three participants. The trial will enrol 40 patients with IDH wild-type, methylation-negative glioblastoma, randomised into two groups to determine the optimal dosage of Ropidoxuridine. An additional 14 patients will receive the optimal dose, with the primary endpoint being survival assessment compared to historical controls. The trial is expected to last 18 to 24 months and involves six enrolment sites, including Georgetown University Medical Center and UNC Medical Center.

Shuttle Pharmaceuticals Holdings announces $4.5M public offering at $1.525 per share, including warrants exercisable at $1.40, expiring in five years. Net proceeds to fund IND-enabling and Phase I/II trials, including $2.3M to Theradex Systems for Ropidoxuridine Phase II trials. Offering expected to close around October 31, 2024.

Shuttle Pharmaceuticals Holdings, Inc. announced the pricing of its public offering for up to 2,950,820 shares of common stock and warrants at $1.525 per share, expecting $4.5 million in gross proceeds. The offering is expected to close on October 31, 2024, with net proceeds intended for clinical trials, payments to Theradex Systems, Inc., and general corporate purposes.

Shuttle Pharmaceuticals Holdings Inc. (Nasdaq:SHPH) shares surged to $2.25/share (+69.17%) after announcing successful dosing of first three patients with ropidoxuridine in a phase 2 trial for glioblastoma, potentially signaling a breakout from a multi-month downtrend.